Celator Pharma (CPXX) 3.10 $CPXX
Celator® Pharmaceuticals to Present at BIO CEO and Investor Conference
PR Newswire - Mon Feb 02, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the BIO CEO and Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET in New York City.
CPXX: 3.10 (+0.07)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Celator blood cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 10:54AM CST
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia
PR Newswire - Tue Jan 20, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML).
CPXX: 3.10 (+0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.94 (+0.10), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), ARWR: 6.77 (+0.21), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), NADL: 2.10 (-0.02), TIF: 89.05 (+0.95), BITA: 62.95 (+2.85), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), TOPS: 1.14 (+0.02), IRMD: 14.61 (-0.35), FMI: 48.88 (+0.17), SRPT: 12.76 (+0.11), REXX: 5.08 (+0.13), LOCM: 0.65 (-0.03), BLFS: 2.14 (+0.06), SNDK: 82.81 (+0.51), AWX: 3.50 (+0.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST
EYES: 8.95 (-0.19), ZIOP: 9.64 (-0.35), OIBR: 2.49 (+0.34), ARWR: 6.77 (+0.21), TKMR: 21.45 (-0.22), SN: 15.21 (-0.12), TIF: 89.05 (+0.95), NBG: 1.61 (+0.18), BMY: 60.04 (+0.56), LULU: 65.98 (-0.06), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), GDP: 3.58 (+0.29), FMI: 48.88 (+0.17), ASNA: 13.11 (+0.58), NPSP: 45.88 (+0.03), AMCO: 1.38 (-0.11), SNDK: 82.81 (+0.51)
Celator Pharma up on Phase 2 results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:11AM CST
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients
PR Newswire - Mon Jan 12, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society. The study manuscript entitled, "Phase 2, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML," appears in the January 15, 2015 issue.
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals awarded USD1.94m from New Jersey's Technology Business Tax Certificate Transfer Programme
M2 - Tue Jan 06, 4:57AM CST
Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) reported on Monday the receipt of about USD1.937m from the sale of its net operating losses under the New Jersey Technology Business Tax Certificate Transfer Programme for 2014.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Receives $1,937,000 from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Mon Jan 05, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it has recently received approximately $1,937,000 from the sale of its net operating losses under the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014.
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals gets European Patent Allowance for taxane prodrug nanoparticle delivery technology
M2 - Fri Dec 19, 7:04AM CST
Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) reported on Thursday that it has received the European Patent Office's allowance for its "Improved Taxane Delivery System" with patent protection for formulations combining docetaxel and other taxanes with molecularly targeted agents.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Receives European Patent Allowance on Nanoparticle Delivery Technology
PR Newswire - Thu Dec 18, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the application of European patent number 2,222,278 was allowed by the European Patent Office. The new patent, "Improved Taxane Delivery System," covers the Company's proprietary taxane prodrug nanoparticle delivery technology and CPX-8, a hydrophobic docetaxel prodrug nanoparticle, which is based on this innovative approach to drug delivery. Celator is currently applying its proprietary CombiPlex technology to drug combinations incorporating targeted agents, such as a combination of docetaxel with a heat shock protein (Hsp90) inhibitor where extended and simultaneous exposure of the two agents to solid tumors at the optimized drug ratio is expected to significantly enhance the efficacy of this combination. This should help establish the broad applicability of the CombiPlex platform in the development of combination cancer therapies. This patent provides protection until November 2028.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Presents Data on CPX-351 at the 56th American Society of Hematology Annual Meeting
PR Newswire - Wed Dec 10, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data on its lead product candidate, CPX-351 (cytarabine:daunorubicin) Liposome for Injection, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, held December 6-9, 2014.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351
PR Newswire - Mon Dec 01, 7:30AM CST
EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML), has completed a planned safety review and recommended that the study continue as planned without any modifications.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals to Present Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Mon Nov 24, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014.
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals' (CPXX) CEO Scott Jackson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 2:02PM CST
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:22PM CST
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Announces Business Update And Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the third quarter ended September 30, 2014.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Stifel 2014 Healthcare Conference on November 19, 2014 at 4:10 p.m. ET in New York City.
CPXX: 3.10 (+0.07)
Celator Pharma reports November 13
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 12:13PM CST
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals to Present at BIO CEO and Investor Conference
PR Newswire - Mon Feb 02, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the BIO CEO and Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET in New York City.
CPXX: 3.10 (+0.07)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Celator blood cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 10:54AM CST
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia
PR Newswire - Tue Jan 20, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML).
CPXX: 3.10 (+0.07)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:46AM CST
CLUB: 6.94 (+0.10), FRO: 2.96 (+0.07), NES: 3.52 (+0.13), ARWR: 6.77 (+0.21), BBW: 20.94 (+0.14), TKMR: 21.45 (-0.22), NADL: 2.10 (-0.02), TIF: 89.05 (+0.95), BITA: 62.95 (+2.85), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), TOPS: 1.14 (+0.02), IRMD: 14.61 (-0.35), FMI: 48.88 (+0.17), SRPT: 12.76 (+0.11), REXX: 5.08 (+0.13), LOCM: 0.65 (-0.03), BLFS: 2.14 (+0.06), SNDK: 82.81 (+0.51), AWX: 3.50 (+0.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:14AM CST
EYES: 8.95 (-0.19), ZIOP: 9.64 (-0.35), OIBR: 2.49 (+0.34), ARWR: 6.77 (+0.21), TKMR: 21.45 (-0.22), SN: 15.21 (-0.12), TIF: 89.05 (+0.95), NBG: 1.61 (+0.18), BMY: 60.04 (+0.56), LULU: 65.98 (-0.06), CPXX: 3.10 (+0.07), AGEN: 5.03 (-0.01), GDP: 3.58 (+0.29), FMI: 48.88 (+0.17), ASNA: 13.11 (+0.58), NPSP: 45.88 (+0.03), AMCO: 1.38 (-0.11), SNDK: 82.81 (+0.51)
Celator Pharma up on Phase 2 results
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 8:11AM CST
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients
PR Newswire - Mon Jan 12, 6:00AM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society. The study manuscript entitled, "Phase 2, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML," appears in the January 15, 2015 issue.
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals awarded USD1.94m from New Jersey's Technology Business Tax Certificate Transfer Programme
M2 - Tue Jan 06, 4:57AM CST
Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) reported on Monday the receipt of about USD1.937m from the sale of its net operating losses under the New Jersey Technology Business Tax Certificate Transfer Programme for 2014.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Receives $1,937,000 from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Mon Jan 05, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a biopharmaceutical company transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it has recently received approximately $1,937,000 from the sale of its net operating losses under the New Jersey Technology Business Tax Certificate Transfer Program for the year 2014.
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals gets European Patent Allowance for taxane prodrug nanoparticle delivery technology
M2 - Fri Dec 19, 7:04AM CST
Biopharmaceutical company Celator Pharmaceuticals (NasdaqCM:CPXX) reported on Thursday that it has received the European Patent Office's allowance for its "Improved Taxane Delivery System" with patent protection for formulations combining docetaxel and other taxanes with molecularly targeted agents.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Receives European Patent Allowance on Nanoparticle Delivery Technology
PR Newswire - Thu Dec 18, 6:00AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the application of European patent number 2,222,278 was allowed by the European Patent Office. The new patent, "Improved Taxane Delivery System," covers the Company's proprietary taxane prodrug nanoparticle delivery technology and CPX-8, a hydrophobic docetaxel prodrug nanoparticle, which is based on this innovative approach to drug delivery. Celator is currently applying its proprietary CombiPlex technology to drug combinations incorporating targeted agents, such as a combination of docetaxel with a heat shock protein (Hsp90) inhibitor where extended and simultaneous exposure of the two agents to solid tumors at the optimized drug ratio is expected to significantly enhance the efficacy of this combination. This should help establish the broad applicability of the CombiPlex platform in the development of combination cancer therapies. This patent provides protection until November 2028.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Presents Data on CPX-351 at the 56th American Society of Hematology Annual Meeting
PR Newswire - Wed Dec 10, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the presentation of data on its lead product candidate, CPX-351 (cytarabine:daunorubicin) Liposome for Injection, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, held December 6-9, 2014.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351
PR Newswire - Mon Dec 01, 7:30AM CST
EWING, N.J., Dec. 1, 2014 /PRNewswire/-- Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome for Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML), has completed a planned safety review and recommended that the study continue as planned without any modifications.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals to Present Data at the 56th American Society of Hematology Annual Meeting
PR Newswire - Mon Nov 24, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, December 6-9, 2014.
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals' (CPXX) CEO Scott Jackson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 2:02PM CST
CPXX: 3.10 (+0.07)
Celator Pharmaceuticals EPS in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:22PM CST
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals Announces Business Update And Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:01PM CST
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the third quarter ended September 30, 2014.
CPXX: 3.10 (+0.07)
Celator® Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 7:30AM CST
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Stifel 2014 Healthcare Conference on November 19, 2014 at 4:10 p.m. ET in New York City.
CPXX: 3.10 (+0.07)
Celator Pharma reports November 13
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 12:13PM CST
CPXX: 3.10 (+0.07)
